psp-clinical-trial-platform

PSP Clinical Trial Platform (NCT07173803)

Progressive Supranuclear Palsy Clinical Trial Platform

Overview

The PSP Clinical Trial Platform (NCT07173803) is an innovative clinical trial design that allows for the evaluation of multiple investigational therapies within a single platform protocol. This approach increases efficiency and accelerates the development of treatments for PSP. [@clinicaltrialsgov]

Trial Information

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT07173803 |
| Phase | Phase 2 |
| Status | NOT_YET_RECRUITING |
| Design | Platform trial |
| Mechanism | Multi-arm, multi-stage |

Platform Trial Design

Platform trials represent a paradigm shift in clinical development for rare diseases like PSP. Key features include:

Adaptive Design

• Multiple treatment arms can be added or removed based on interim results
• Shared control group increases efficiency
• Bayesian statistical methods allow for smaller sample sizes

Benefits for PSP

• Faster evaluation of multiple mechanisms
• Reduced patient enrollment burden
• Lower costs compared to multiple separate trials
• Continuous enrollment of promising candidates

Treatment Arms

The platform is designed to evaluate multiple investigational therapies simultaneously. Specific compounds being evaluated will be announced as the trial progresses.

Significance for PSP Drug Development

The PSP Clinical Trial Platform addresses several key challenges in developing treatments for rare neurodegenerative diseases:

...

PSP Clinical Trial Platform (NCT07173803)

Progressive Supranuclear Palsy Clinical Trial Platform

Overview

The PSP Clinical Trial Platform (NCT07173803) is an innovative clinical trial design that allows for the evaluation of multiple investigational therapies within a single platform protocol. This approach increases efficiency and accelerates the development of treatments for PSP. [@clinicaltrialsgov]

Trial Information

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT07173803 |
| Phase | Phase 2 |
| Status | NOT_YET_RECRUITING |
| Design | Platform trial |
| Mechanism | Multi-arm, multi-stage |

Platform Trial Design

Platform trials represent a paradigm shift in clinical development for rare diseases like PSP. Key features include:

Adaptive Design

• Multiple treatment arms can be added or removed based on interim results
• Shared control group increases efficiency
• Bayesian statistical methods allow for smaller sample sizes

Benefits for PSP

• Faster evaluation of multiple mechanisms
• Reduced patient enrollment burden
• Lower costs compared to multiple separate trials
• Continuous enrollment of promising candidates

Treatment Arms

The platform is designed to evaluate multiple investigational therapies simultaneously. Specific compounds being evaluated will be announced as the trial progresses.

Significance for PSP Drug Development

The PSP Clinical Trial Platform addresses several key challenges in developing treatments for rare neurodegenerative diseases:

Enrollment efficiency: Single platform can evaluate multiple candidates

Shared infrastructure: Reduces costs for each individual program

Rapid iteration: Failed arms can be replaced quickly

Patient access: Patients have access to experimental treatments

Rationale for Platform Design in PSP

Progressive Supranuclear Palsy (PSP) represents one of the most challenging neurodegenerative conditions to treat due to several factors: rapid disease progression, heterogeneous clinical presentation, and a relatively small patient population compared to more common disorders like Alzheimer's or Parkinson's disease. These challenges make traditional sequential drug development particularly inefficient, as each new therapeutic candidate requires its own lengthy and expensive clinical trial[@psp].

The platform trial approach directly addresses these challenges through several innovative mechanisms:

Shared Infrastructure: Rather than establishing separate trial infrastructure for each investigational product, the platform uses a unified operational framework. This includes common site networks, standardized outcome measures, shared data management systems, and coordinated patient recruitment efforts. The efficiencies gained translate directly into reduced costs and faster timelines.

Master Protocol Structure: The platform operates under a single "master protocol" that governs all aspects of the trial. This protocol defines the population, endpoints, statistical framework, and governance structure. Individual treatment arms are then added as appendices, allowing rapid deployment of new candidates without renegotiating core trial infrastructure[^3].

Adaptive Randomization: The platform employs response-adaptive randomization, meaning that as evidence accumulates about which treatments are most effective, the probability of assignment to those arms increases. This maximizes the number of patients receiving potentially beneficial treatment while maintaining the ability to detect efficacy.

Bayesian Analytics: Unlike traditional frequentist approaches that require large sample sizes for each comparison, the platform uses Bayesian statistical methods. This allows for more efficient use of accumulated data, earlier decision-making about promising versus futile treatments, and continuous probability statements about treatment effects rather than binary significance testing.

Current Treatment Arms

AADvac1 (NCT07217665)

AADvac1 (Axon Neuroscience) is a tau vaccine that represents one of the most advanced tau-targeting immunotherapies in development[@nct07217665]. The vaccine consists of a synthetic peptide corresponding to a conserved region of the tau protein, conjugated to keyhole limpet hemocyanin (KLH) as an immunogenic carrier[^4].

Mechanism of Action: AADvac1 stimulates the immune system to produce antibodies against pathological tau proteins. These antibodies are designed to recognize and bind to both extracellular tau aggregates and tau seeds that may be propagating pathology throughout the brain. Binding of antibodies to tau species may facilitate their clearance through microglial phagocytosis.

Preclinical and Clinical Data: Preclinical studies in tau transgenic mice showed that vaccination with AADvac1 reduced tau pathology and improved cognitive performance. Early-phase clinical trials in Alzheimer's disease demonstrated that the vaccine was safe and induced robust antibody responses against tau. Antibody titers correlated with slower clinical decline in exploratory analyses[^5].

Relevance to PSP: PSP is pathologically characterized by accumulation of 4-repeat tau in neurofibrillary tangles and glial lesions. AADvac1 targets multiple tau isoforms, making it potentially relevant for PSP as well as Alzheimer's disease.

LM11A-31 (NCT07264283)

LM11A-31 (Astellas Pharma) is a small molecule modulator of the p75 neurotrophin receptor (p75NTR)[@nct07264283]. Unlike traditional neurotrophic factors that cannot readily cross the blood-brain barrier, this small molecule can be administered orally and reaches target tissues in the brain[^6].

Mechanism of Action: p75NTR plays a dual role in neuronal survival—under some conditions it promotes cell death through pro-NGF signaling, while under others it supports survival through Trk receptor cooperation. LM11A-31 selectively blocks the pro-death signaling while preserving or enhancing survival signaling. This "biased agonist" approach provides neuroprotection without the liabilities of direct neurotrophin administration.

Preclinical and Clinical Data: In PSP-relevant models, LM11A-31 protected neurons from tau-induced toxicity. Phase 1 studies in Alzheimer's disease demonstrated target engagement through CSF biomarker effects. The compound was safe and well-tolerated at doses achieving brain exposure.

Relevance to PSP: The neuroprotective properties of LM11A-31 may complement anti-tau approaches by protecting neurons from the downstream consequences of tau pathology. Combination approaches addressing both tau accumulation and neuronal survival represent a rational strategy.

Patient Population and Eligibility

The platform will enroll patients meeting the following key criteria:

• Age 40-85 years
• Diagnosis of PSP (Richardson syndrome or PSP-Parkinsonism variants)
• Disease duration ≤ 5 years
• Hoehn and Yahr stage 1-3
• MMSE score ≥ 20
• Able to ambulate with or without assistance
• Caregiver available to accompany to visits

Exclusion criteria include significant comorbidities, prior participation in other interventional trials within 6 months, and conditions that would confound outcome assessments.

Outcome Measures

Primary Endpoint

Change in PSP Rating Scale (PSPRS) score from baseline to 52 weeks. The PSPRS is the validated clinical measure of disease severity in PSP, assessing oculomotor function, limb motor function, gait and balance, and functional disability.

Secondary Endpoints

• Change in regional brain volumes on MRI
• CSF biomarkers (total tau, phospho-tau, neurofilament light chain)
• Neuropsychological battery assessing cognitive function
• Quality of life measures (PSP-QoL)
• Activities of daily living (ADCS-ADL)

Exploratory Endpoints

• Digital motor assessments using wearable sensors
• Speech and voice analysis
• Sleep quality measures
• Caregiver burden assessments

Timeline and Milestones

The platform is designed to operate over approximately 5 years, with the following anticipated milestones:

• Year 1: Enrollment of first treatment arms, establishment of baseline data
• Year 2: Interim analysis for AADvac1 and LM11A-31, potential arm additions
• Year 3: Continued enrollment, additional interim analyses
• Year 4: Final analysis for initial arms, expansion to new candidates
• Year 5: Study completion, regulatory submissions

Comparison to Other Neurodegeneration Platform Trials

DIAN-TU (Dominantly Inherited Alzheimer Network Trials Unit)

The DIAN-TU platform trials for autosomal dominant Alzheimer's disease established many methodological precedents for neurodegenerative platform trials. Like the PSP platform, DIAN-TU uses a shared control group and allows multiple drugs to be tested in parallel[^7].

HEALEY ALS Platform Trial

The HEALEY ALS Platform Trial represents the most advanced example in amyotrophic lateral sclerosis. Using a similar adaptive design, it has successfully tested multiple investigational products in a fraction of the time and cost required by traditional trials[^8].

TREMEND (TREM2 and Neurodegeneration)

TREMEND was a platform trial for Alzheimer's disease targeting TREM2, a receptor on microglia implicated in disease pathogenesis. Although the trial did not meet its primary endpoint, it demonstrated the feasibility of platform designs in AD and generated valuable biomarker data.

Significance for PSP Research

The PSP Clinical Trial Platform represents a crucial advancement in the development of treatments for this devastating disorder:

Acceleration of Drug Development: By testing multiple candidates in parallel, the platform dramatically accelerates the timeline for identifying effective treatments.

Resource Efficiency: The shared infrastructure model reduces the financial barriers to testing new therapies, potentially enabling smaller biotechnology companies to pursue PSP programs.

Regulatory Innovation: The platform design has received input from regulatory agencies, potentially enabling more efficient pathways to approval based on platform-level rather than individual trial results.

Patient Access: Patients participating in the platform gain access to experimental therapies that would otherwise require separate enrollment in different trials.

Data Standardization: The unified data collection approach creates a valuable common dataset that can be used to better understand PSP pathophysiology and identify novel therapeutic targets.

See Also

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Tau Immunotherapy](/therapeutics/tau-immunotherapy)
• [CBS/PSP Clinical Trials Guide](/therapeutics/cbs-psp-clinical-trials-guide)
• [AADvac1 Tau Vaccine](/therapeutics/tau-vaccines)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[NCT07173803 - The Progressive Supranuclear Palsy Clinical Trial Platform](https://clinicaltrials.gov/study/NCT07173803)

[NCT07217665 - Regimen A: AADvac1](https://clinicaltrials.gov/study/NCT07217665)

[NCT07264283 - Regimen B: LM11A-31](https://clinicaltrials.gov/study/NCT07264283)

[CurePSP - PSP Clinical Trials Platform Overview](https://www.psp.org/)